Should all patients with duodenal adenocarcinoma be considered for aggressive surgical resection?

Hurtuk, Michael G.; Devata, Sumana; Brown, Kimberly M.; Oshima, Kiyoko; Aranha, Gerard V.; Pickleman, Jack; Shoup, Margo

doi:10.1016/j.amjsurg.2006.09.013

Cited by 37 publications

(49 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Long-term survival for duodenal adenocarcinoma is inconsistent in the literature, and the biology of duodenal adenocarcinoma is poorly understood. This is apparent in cases of larger tumors, which interestingly were less likely to be invasive and patients with these tumors had improved survival [9,10]. Nevertheless, the only possibility of cure of primary duodenal adenocarcinoma is considered a radical resection.…”

Section: Discussionmentioning

confidence: 97%

Synchronous primary duodenal bulb and cecal adenocarcinoma: case report and short review of the literature

et al. 2012

View full text Add to dashboard Cite

Background: Primary duodenal adenocarcinoma is a rare entity with an uncertain biologic behaviour whose diagnosis is usually achieved by endoscopy and biopsy. However, it lacks specific symptoms and its diagnosis may be delayed with poor prognosis. Villous adenomas are considered as premalignant lesions with high risk malignant transformation.Methods: We report a rare case of a patient with two synchronous adenocarcinomas, one of the first portion of the duodenum as a villous tumor and the other in cecum colon. The patient submitted successfully to pacreatoduodenectomy and right hemicolectomy, while postoperatively received also adjuvant chemotherapy.Results: Seventeen months after the operations the patient is alive with no evidence of recurrent or metastatic disease.Conclusions: The radical resection of primary duodenal adenocarcinoma is considered the treatment of choice, which should be accompanied by adjuvant chemotherapy preventing a recurrence at distant sites.

show abstract

Section: Discussionmentioning

confidence: 97%

Synchronous primary duodenal bulb and cecal adenocarcinoma: case report and short review of the literature

et al. 2012

View full text Add to dashboard Cite

show abstract

“…L'adénocarcinome duodénal est une tumeur inhabituelle représentant moins de 0,4 % de l'ensemble des tumeurs du tractus gastro-intestinal [1,2], près de 45 % de ces adénocar-cinomes siègent préférentiellement au niveau des troisième et quatrième portions du duodénum [3]. Dans une étude portant sur 400 patients avec tumeurs périampullaires, l'incidence de l'adénocarcinome duodénal varie entre 4 et 6 % des tumeurs étudiées [4,5].…”

Section: Discussionunclassified

Aspect anatomoradiologique de l’adénocarcinome duodénal: à propos d’un cas

et al. 2010

View full text Add to dashboard Cite

L'adénocarcinome duodénal est une tumeur exceptionnelle. Les manifestations cliniques sont non spécifiques et posent un problème diagnostique, d'où l'intérêt des explorations endoscopiques et radiologiques. La duodénopancréa-tectomie céphalique est le traitement de choix, surtout chez des patients sans métastases ganglionnaires. Nous rapportons l'observation d'une patiente de 52 ans en montrant l'aspect anatomoradiologique de cette localisation rare dans la littérature. Le recul de cette observation est d'une année. Mots clés Adénocarcinome · Tumeur duodénale · Tomodensitométrie · PronosticAbstract A duodenal adenocarcinoma is a very rare type of tumour. The clinical signs are not specific, and they pose a diagnosis problem; hence the usefulness of endoscopic and radiological explorations. Cephalic duodenopancreatectomy is the first-choice treatment, especially in patients without ganglionic metastases. We report on the observation of a female patient, aged 52, showing the anatomical and radiological aspect of this location, which is rare in the literature. The follow-up period for this observation is one year.

show abstract

“…Die beobachteten 5-Jahres-Überle-bensraten nach R0-Resektion zeigen hingegen -berücksichtigt man die zumeist begrenzten Fallzahlen -relativ geringe Schwankungen um die 40% [19][20][21][22][23][24][25][26][27]. In Übereinstimmung damit ergab die Auswertung der National Cancer Data Base [28] für die Diagnosejahrgänge 1985 bis 1990 für 1265 Patienten mit Tumorresektion eine 5-Jahres-Überlebensrate von 40,3%.…”

Section: Therapieunclassified